Kornimate/medical-research-clean huggingface dataset:
study of human papillomavirus related genital pathology among hiv positive women

Conditions: HIV Infections

Summary: this study is a multicentre cohort study with inclusion throughout the full duration of the study. the primary objective is the study of human papillomavirus related genital pathology in hiv positive women. the secondary objective are: 1. to study the characteristics of hpv infection and related disease in the context of long term haart and hiv infection ; 2. to study the characteristics of atypical cells of uncertain significance detected in pap smears, whose prevalence has dramatically increased in the last years; 3. to describe cervical cancers observed in the cohort 4. to study the evolution of recurrent high-grade lesions after surgery 5. to describe the evolution of vaginal lesions developed after hysterectomy for high-grade lesions ; 6. to describe the specific aspects of surgery for the treatment of cervical lesions according to the specific localization in the endocervix in hiv-positive women ; 7. to study the in situ t cell hpv specific response in cervical lesions and the relationship between virological and clinical parameters, host immune status and natural history of lesions ; 8. to initiate a prospective study on anal hpv infection and related disease among women infected with hiv. 9. to initiate a study on therapeutic and/or prophylactic hpv vaccines in the context of immunosuppression and a high rate of hpv infection ;

data were be collected into evaluate: * analysis of prognostic factors (cd4, antiviral therapy) of cervical lesions, using cox models. * estimation of rates of incidence of high grade lesions, of recurrence after surgical treatments using kaplan meier tests. * logistic regression analysis for the study of factors associated with complete excision after surgical treatment. * sir (standardised incidence rate) evaluation for cervical cancer study procedures are annual follow-up in case of normal pap smear, biannual follow-up in case of cervical lesions. surgical management of high grade lesions.

Eligibility criteria:
inclusion criteria: * women \> 18 years old * attending outpatient gynecology consultation * hiv positive * with written informed consent * on social security exclusion criteria: * unaffiliated to the social healthy security french system

Keywords: human papillomavirus follow up
montelukast back to school asthma study (0476-340)

Conditions: Asthma

Summary: this study, in children with chronic asthma, evaluates the number of days of worsening asthma during 8 weeks of treatment with montelukast after treatment is started for the first day of school.


Eligibility criteria:
inclusion criteria: * male and female non-smoking participants, ages 6 to 14 years, with chronic asthma, history of at least one asthma exacerbation associated with a cold within the past year and a documented history of asthma that required treatment with any asthma medication within 6 months prior to visit 1 exclusion criteria: * participant cannot have any other acute or chronic pulmonary disorder, or hospitalization for asthma more than three times within one year prior to signing informed consent
a clinical study of transaxillary endoscopic and open thyroidectomy for ptc

Conditions: Papillary Thyroid Cancer

Summary: to evaluate the feasibility and safety of gasless transaxillary posterior endoscopic thyroidectomy (resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) and open radical thyroidectomy (resection of thyroid lobe and isthmus, lymph node dissection in the central area of the affected side) as the current standard surgical treatment mode in terms of feasibility and safety of radical thyroidectomy.

subjects that suffering from papillary thyroid carcinoma will be randomized into study group (gasless transaxillary posterior endoscopic thyroidectomy ) or control group (conventional open thyroidectomy). measure the outcomes as following, early complication rate, life quality score, the number of dissected lymph nodes, the volume of residual gland, 3-year recurrence rate, operation duration, hospital stays, hospitalization expense, and inflammatory and immune response.

Eligibility criteria:
inclusion criteria: * the patient's informed consent; * 18 years old \< age \< 70 years old; * papillary thyroid carcinoma (bethesda grade v-vi) was pathologically diagnosed by fine needle aspiration biopsy of the primary thyroid tumor before surgery; * color doppler ti-rads 4c-5 of primary thyroid tumor; * the preoperative clinical staging is t1, n0-1a, m0 (see diagnostic criteria for details; according to ajcc-8th tnm tumor staging); * it is expected that r0 surgical results can be obtained by performing single thyroid lobectomy and isthmus resection + ipsilateral central lymph node dissection; * preoperative asa score i-iii. exclusion criteria: * pregnant or lactating patients; * suffering from serious mental illness; * preoperative imaging examinations suggest that the tumor is located in the thyroid isthmus or involves bilateral lobes; * preoperative imaging examinations suggest the possibility of cervical lateral lymph node or distant metastasis; * hashimoto's thyroiditis combined with hyperthyroidism or abnormal thyroid function; * history of neck surgery; * history of thyroid surgery (including ablation therapy for thyroid nodules); * family history of thyroid cancer; * history of childhood ionizing radiation exposure; * history of other malignant diseases within 5 years; * a history of unstable angina or myocardial infarction within 6 months; * history of cerebral infarction or cerebral hemorrhage within 6 months; * history of continuous systemic corticosteroid therapy within 1 month; * concurrent surgical treatment of other diseases is required; * patients who are judged by the investigator to be unsuitable to participate in this trial.

Keywords: endoscopic thyroidectomy
effects of sage on memory and mental performance in alzheimer's disease patients

Conditions: Alzheimer Disease

Summary: the purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with alzheimer's disease. study hypothesis: the administration of sage will improve cognitive function in patients with mild alzheimer's disease.

the herb sage has been shown to enhance memory and mental function in healthy, young adults. however, studies assessing the herb's effectiveness in older adults with symptoms of alzheimer's disease are limited. this study will determine the effect of sage extract on the cognitive function of patients with mild alzheimer's disease. this study will last 6 weeks and will comprise 4 study visits, approximately 10 days apart. participants will be randomly assigned to receive either sage pills or no treatment during each 10-day period. the treatment assignments will be switched in 10-day intervals, so that during the course of the study, each participant will undergo two periods of sage treatment and two periods without treatment. at each study visit, participants will undergo cognitive testing, including tests to determine attention, memory, and visual cognition. participants will also undergo an electroencephalogram (eeg) and an electrocardiogram (ecg) at each visit.

Eligibility criteria:
inclusion criteria: * diagnosis of mild alzheimer's disease * partner, friend, child, spouse, or relative willing to accompany participants to all study visits, provide informed consent, monitor participants' pill-taking, and communicate changes in participants' health during the study exclusion criteria: * significant medical illness other than alzheimer's disease
treatment of fibromyalgia using deep shaped-field transcranial magnetic stimulation a clinical feasibility study

Conditions: Fibromyalgia

Summary: deep shaped-field transcranial magnetic stimulation is a new type of transcranial magnetic stimulation technology which may provide a drug-free method for treating fibromyalgia. the purpose of this study is to determine the effectiveness and the durability of effect of deep shaped-field repetitive transcranial magnetic stimulation (rtms) in men and women diagnosed with fibromyalgia.


Eligibility criteria:
inclusion criteria: * fibromyalgia as diagnosed by american college of rheumatology (acr) criteria. * moderate or severe pain from fibromyalgia despite current treatment regimen. * will not become pregnant during study. exclusion criteria: * seizure disorder. * metal implants on or in brain, spinal cord, ear, eye or heart. * current use of proconvulsant medications (e.g., bupropion). * taking oral amitriptyline \> 100 mg once daily at bedtime. * nonscheduled analgesic, anticonvulsant or antidepressant medications. * severe depression or suicidality. * other significant psychiatric disorder. * previous use of tms.

Keywords: fibromyalgia transcranial magnetic stimulation pain
pycnogenol for the treatment of lymphedema

Conditions: Lymphedema

Summary: the objectives of this study are to evaluate the effectiveness of pycnogenol (french maritime pine bark extract) for arm lymphedema in women following treatment for breast cancer, to evaluate the accuracy and sensitivity of bioelectric impedence as a measurement of lymphedema of the arm, and to validate the proposed arm lymphedema quality-of-life questionnaire.


Eligibility criteria:
inclusion criteria: * \> 6 months from last surgical and/or radiation treatment to the affected axilla * unilateral lymphedema of the upper extremity exclusion criteria: * may not be receiving or be scheduled to receive cytotoxic or radiation chemotherapy treatment while on this study

Keywords: lymphedema of the arm in breast cancer survivors
tumorgraft- guided therapy for improved outcomes in head and neck squamous cell cancer- a feasibility study

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: primary objectives: 1. evaluate the feasibility of rapidly accruing 30 participants with recurrent metastatic head and neck squamous cell carcinoma for the development of patient derived xenographs (pdx) from fresh, real time biopsies in which sensitivity to \< 4 ontario funded chemotherapeutic regimen will be tested. written feedback to the primary oncologist will be provided. 2. there is also a curative intent cohort of 30 participants undergoing surgical resection with curative intent. these pdx models will undergo exome sequencing with written feedback. 3. feasibility in both surgical and recurrent cohorts will be a measure of i) engraftment rate, ii) patient status at the time of drug testing completion and iii) rate of accrual.

tumour samples from 30 participants with hnscc that undergone curative surgery will be used to establish patient-derived xenografts (pdxs). these tumours will also undergo exome sequencing. this will provide a biobank of pdx models with available genomic information for future research projects. another 30 participants with recurrent or metastatic hnscc (rmhnscc) will be recruited to this study. pdx models will be developed from these patient tumours, followed by genomic sequencing. pdx models are developed by transplanting small tumour pieces into immunocompromised mice. these mice are then treated with different available drugs for rmhnscc at the discretion of their medical oncologist. these mice will be then followed up to examine the tumour response to treatments. when studied in clinic, pdx models have shown high correlation with patient response to the treatment. the pdx drug testing results will be provided to the treating medical oncologist to guide care at the oncologists discretion. investigators' hope is that improved chemotherapy responses are observed with this strategy.

Eligibility criteria:
inclusion criteria: 1. patients with recurrent metastatic squamous cell carcinoma of the head and neck. 2. lesion amenable to biopsy (1 cm or more) 3. lesion capable of yielding 4 biopsy cores 4. 18 years or older 5. capable of providing and signing for informed consent exclusion criteria: 1. cognitive impairment prohibitive to providing informed consent 2. pregnant or lactating women.

Keywords: head and neck cancer patient derived xenograft chemotherapy metastases
efficacy and safety of fucicort® lipid cream compared to combination treatment with fucidin® cream followed by betamethasone (lianbang beisong®) cream and fucicort® lipid cream vehicle in clinically infected atopic dermatitis/eczema

Conditions: Infected Atopic Dermatitis/Eczema

Summary: the trial is designed to compare the efficacy and safety of fucicort® lipid cream with the combination treatment of fucidin® cream followed by betamethasone (lianbang beisong®) cream, or fucicort® lipid cream vehicle, when applied twice daily for two weeks. the trial is designed to demonstrate that treatment with fucicort® lipid cream is not inferior to the combination treatment with the mono component drugs, fucidin® cream followed by betamethasone (lianbang beisong®) cream and that treatment with fucicort® lipid cream is superior to the treatment with fucicort® lipid cream vehicle. this is a 3-arm, parallel group, active- and vehicle-controlled trial comparing the efficacy and safety after 14 days treatment of fucicort® lipid cream, to fucidin® cream followed by betamethasone (lianbang beisong®) cream, or fucicort® lipid cream vehicle, in subjects with clinically infected ad/eczema.


Eligibility criteria:
inclusion criteria: * diagnosis of ad/eczema as defined by williams's criteria with clinical signs of infected ad/eczema on trunk and/or extremities such as fluid drainage, blistered skin, white or yellow pus, severe itchiness and new burning sensation * a minimum score of 1 for each of the signs in the m-easi score in at least one of the pre-defined body areas (trunk and/or extremities) * subjects between 2 and 65 years of age exclusion criteria: * history of concurrent diseases that could interfere with trial assessments or pose a safety concern * subjects with other skin lesions, e.g. scarring, tattoos, or hyperpigmentation on the treatment area that could interfere with assessments * clinical findings such as severe heart, liver, kidney and lung deficiency, which will be impacted by the trial procedures at the investigator's discretion * subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the last 4 weeks prior to randomisation at investigator's discretion * use of prohibited medication, i.e. 1. systemic treatment with immunosuppressive or immunomodulating drugs(including leigongteng) or corticosteroids within 28 days prior to randomisation 2. use of topical or systemic antibiotics and anti-histamines within 14 days prior to randomisation 3. phototherapy (e.g. puva, uva or uvb therapy) within 28 days prior to randomisation 4. topical treatment with immunomodulators (e.g. pimecrolimus, tacrolimus) within 14 days prior to randomisation 5. topical treatment with corticosteroids or any other topical treatment within 7 days prior to randomisation 6. use of any non-prescribed systemic or cutaneous medication within 7 days prior to randomisation 7. the use of analgesics at the discretion of the investigator is allowed before and during the trial
a pilot study of perihepatic phlebotomy during hepatic resections

Conditions: Liver Cancer

Summary: the purpose of this study is to draw blood from vessels near the liver in patients undergoing liver surgery. this will be performed in both patients with cancer in order to learn more about circulating tumor cells, proteins and dna mutations in the blood. the blood in patients with colorectal cancer with liver metastases will be compared to blood taken from patients that do not have cancer that do not have cancer. inclusion of patients with benign pathology will allow for the establishment of "normal" values which currently do not exist. we will then study whether tumor mutations can be used to predict recurrence and survival patterns.


Eligibility criteria:
inclusion criteria: * all patients with resectable crlm without extrahepatic metastases confirmed by tissue diagnosis or radiologic exam who are undergoing hepatic resection. * all patients undergoing hepatic arterial infusion pump placement with or without without hepatic resection. * patients may have synchronous or metachronous crlm * patients may have received prior cytotoxic (must be off for at least 2 weeks prior to surgery) or anti-angiogenic therapy (must be off for at least 6 weeks prior to surgery). specific drugs are listed below. * 5-fu based chemotherapy - 2 weeks off * bevacizumab - 6 weeks off * cetuximab or panitumumab - 2 weeks off * control patients will include patients consented for pancreaticoduodenectomy for benign or pre-neoplastic lesions. if lesions assumed to be benign turn out to be malignant on final pathology, the blood will be discarded and the patient replaced. * patients undergoing a two-stage hepatectomy resection, or who are reevaluated for a second hepatectomy, will be considered for reenrollment to protocol exclusion criteria: * evidence of extra-hepatic disease on pre-operative imaging or at operative exploration, excluding the primary colorectal tumor * those with known bleeding or clotting diatheses * patients diagnosed with chronic inflammatory diseases such as lupus, rheumatoid arthritis, psoriasis, ulcerative colitis, crohns disease, etc. * pre- or intra-operative evidence of portal vein thrombosis or hypertension * patients who have taken immune modulating agents in the past 8 weeks including steroids, anti-tnf-α, interferon etc. patients taking a single dose of decadron as part of a chemotherapy regimen will not be excluded from the study. * patients who take daily anti-inflammatory medications such as cox-2 inhibitors or high dose nsaids. patients taking a daily aspirin or acetaminophen or occasional anti-inflammatory medications will not be excluded from the study. * if at the discretion of the operating surgeon, blood acquisition would lead to undue morbidity, the patient will be excluded and replaced * attending physicians authorized to obtain informed consent may exercise discretion in excluding individuals for appropriate medical or other reasons.

Keywords: blood draw perihepatic phlebotomy 12-236
the effect of a psychosensory therapy

Conditions: Joint Replacement Surgery

Summary: this is a prospective study looking at the impact of psychosensory therapy and how it can diminish pain and consumption of pain medications. the primary study objective is to evaluate the change in visual analogue score (vas) score assessing for pain from baseline, every day of inpatient stay, 7 days after leaving hospital (via phone), and 3 months post-op(via phone) and to correlate the psychosensory therapy and overall use of pain medications/narcotics.

the study will aim to enroll 50 subjects. 25 subjects will receive placebo therapy which will be dummy movements while the other 25 will receive psychosensory therapy. the treatment group will involve a touch technique called havening.

Eligibility criteria:
inclusion criteria: * patient undergoing joint replacement surgery (hip and knee only) * patient is willing to participate in pre- and postoperative surveys exclusion criteria: * patients who have undergone joint replacement surgeries * history of chronic narcotic use (more than 30mg morphine dose)

Keywords: hip knee replacement surgery
non-invasive biomarkers for early detection of lung cancers

Conditions: Lung Cancer

Summary: recent studies have shown that low-dose chest ct scans can detect lung cancers in high-risk populations (age \>50yo, \>30 pack-years of tobacco use), and can lower cancer mortality. unfortunately, the vast majority of "positive" findings on these ct scans are benign (\>95%). currently, an inordinate amount of expensive follow-up testing is required for these patients to try to prove who among them truly has a cancer. several new emerging non-invasive and potentially cheaper tests are now being investigated to help differentiate patients with cancers versus just benign lung nodules. these new tests include a new type of sputum analysis, a breath analysis, a blood test measuring certain tumor markers, a blood test looking for auto-antibodies, and a standard pet/ct scan. each of these tests have different sensitivity and specificity rates when looking for lung cancer, and it is unclear which test is best. this study will employ a panel of all 5 of these non-invasive tests on an initial cohort of 50 patients with recently diagnosed lung cancer to try to measure the sensitivity of the tests. a follow-on study will then perform the same panel of tests on 300 lung nodule patients to see which test, or combination of tests, gives the best overall accuracy in terms of predicting who really has lung cancer. it is hoped that the use of such a panel could lead to dramatically decreased need for expensive and morbid invasive testing for this population.

the study revolves around specifying the exact signatures and accuracy associated with discriminating between benign and malignant spns for each of the biomarkers in the specific high risk cohort under the nlst screening protocol. to help identify and quantify these signatures, we will evaluate specifically the volatile signature in the exhaled breath, the accuracy of luced sputum detection, the profile of tumor markers and the specifications of auto-antibodies through immunoassays and orbitrap technology, and the pet/ct in patients already diagnosed with lung cancer.

Eligibility criteria:
inclusion criteria: * newly diagnosed cancer, prior to treatment exclusion criteria: * prior treatment for this cancer * a history of any other cancer

Keywords: biomarkers lung cancer solitary pulmonary nodules spn breath analysis voc volatile organic compounds sputum auto-antibodies
a trial using cd133 enriched bone marrow cells following primary angioplasty for acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: an international, multi-centre, double-blind, randomised, placebo-controlled clinical trial with central core lab analyses to determine the safety of intra-coronary infusion of enriched cd133+, bone marrow-derived, autologous progenitor cells in patients 5-10 days after acute percutaneous coronary revascularization (primary pci) for st-segment elevation myocardial infarction (stemi).


Eligibility criteria:
inclusion criteria: * primary pci for acute stemi between 2-24 hours after onset of chest pain. * st-segment elevation \>=2mm in \>=3 adjacent leads. * presence of severe hypokinesia and/or akinesia in \>=2 adjacent segments on echocardiogram at 48-72 hrs after primary pci. * age between 20 and 75 years. exclusion criteria: * pregnant or lactating. * prior history of myocardial infarction before index event. * decompensated congestive heart failure. * pre-existent lv dysfunction (ef \<45% prior to admission) * cardiomyopathy. * previous cardiac surgery. * congenital heart disorder. * serum creatinine \>200 mmol/l. * presence of permanent pacemaker or implantable defibrillator. * contraindication to bone marrow aspiration. * history of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma and/or cervical carcinoma. * sustained or inducible vt \>48 hours post primary pci. * three vessel coronary artery disease necessitating intervention within 4 months. * immune compromise including chronic human immunodeficiency virus (hiv), hepatitis b virus (hbv) and hepatitis c virus (hcv) infection. * presence of chronic systemic inflammatory disorders. * previous autologous or allogeneic bone marrow or peripheral stem cell transplant or prior solid organ transplantation. * low hemoglobin, white blood cell, absolute neutrophil and/or platelet count. * any condition associated with a life expectancy of less than 6 months. * participation in unrelated research involving investigational pharmacological agent(s) 30 days before planned dosing. * current alcohol or drug abuse. * inability to provide written informed consent.

Keywords: acute myocardial infarction celltherapy bone marrow